GH vs. IQV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GH and IQV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | GH | IQV |
|---|---|---|
| Company Name | Guardant Health, Inc. | IQVIA Holdings Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Life Sciences Tools & Services |
| Market Capitalization | 8.15 billion USD | 34.10 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | October 4, 2018 | May 9, 2013 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of GH and IQV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GH | IQV |
|---|---|---|
| 5-Day Price Return | 6.28% | -1.83% |
| 13-Week Price Return | 27.98% | 23.81% |
| 26-Week Price Return | 55.45% | 19.63% |
| 52-Week Price Return | 205.95% | -10.99% |
| Month-to-Date Return | 4.55% | 5.61% |
| Year-to-Date Return | 113.81% | 2.08% |
| 10-Day Avg. Volume | 2.25M | 1.49M |
| 3-Month Avg. Volume | 2.47M | 1.79M |
| 3-Month Volatility | 52.89% | 48.37% |
| Beta | 1.59 | 1.37 |
Profitability
Return on Equity (TTM)
GH
-246.60%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
GH has a negative Return on Equity of -246.60%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
IQV
19.96%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, IQV’s Return on Equity of 19.96% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
GH
-49.93%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
GH has a negative Net Profit Margin of -49.93%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
IQV
7.88%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
IQV’s Net Profit Margin of 7.88% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
GH
-54.54%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
GH has a negative Operating Profit Margin of -54.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
IQV
13.85%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
IQV’s Operating Profit Margin of 13.85% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | GH | IQV |
|---|---|---|
| Return on Equity (TTM) | -246.60% | 19.96% |
| Return on Assets (TTM) | -29.04% | 4.50% |
| Net Profit Margin (TTM) | -49.93% | 7.88% |
| Operating Profit Margin (TTM) | -54.54% | 13.85% |
| Gross Profit Margin (TTM) | 62.84% | 34.25% |
Financial Strength
Current Ratio (MRQ)
GH
3.71
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
GH’s Current Ratio of 3.71 is exceptionally high, placing it well outside the typical range for the Health Care Providers & Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
IQV
0.84
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
IQV’s Current Ratio of 0.84 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
GH
16.78
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
With a Debt-to-Equity Ratio of 16.78, GH operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
IQV
2.68
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.68, IQV operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
GH
-150.95
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
GH has a negative Interest Coverage Ratio of -150.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
IQV
3.68
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
IQV’s Interest Coverage Ratio of 3.68 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | GH | IQV |
|---|---|---|
| Current Ratio (MRQ) | 3.71 | 0.84 |
| Quick Ratio (MRQ) | 3.19 | 0.81 |
| Debt-to-Equity Ratio (MRQ) | 16.78 | 2.68 |
| Interest Coverage Ratio (TTM) | -150.95 | 3.68 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GH
0.00%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
GH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
IQV
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
IQV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
GH
0.00%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
GH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
IQV
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
IQV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | GH | IQV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
GH
--
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
P/E Ratio data for GH is currently unavailable.
IQV
27.64
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
IQV’s P/E Ratio of 27.64 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
GH
9.91
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
With a P/S Ratio of 9.91, GH trades at a valuation that eclipses even the highest in the Health Care Providers & Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
IQV
2.18
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
In the lower quartile for the Life Sciences Tools & Services industry, IQV’s P/S Ratio of 2.18 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
GH
35.72
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
At 35.72, GH’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
IQV
4.72
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
IQV’s P/B Ratio of 4.72 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | GH | IQV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 27.64 |
| Price-to-Sales Ratio (TTM) | 9.91 | 2.18 |
| Price-to-Book Ratio (MRQ) | 35.72 | 4.72 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | 17.01 |